| Overview |
| bs-70039g-100ul |
| ChAT (Choline Acetyltransferase) Antibody |
| WB, IHC |
| Specific for endogenous levels of the ~70 kDa choline acetyltransferase protein. |
| Human, Mouse, Rat, Chicken, Guinea Pig, Non-Human Primate |
| Specifications |
| Unconjugated |
| Goat |
| Recombinant human choline acetyltransferase |
| Polyclonal |
| IgG |
| Lot Dependent |
| Affinity purification |
| PBS + 5 mg/ml BSA + 0.2% NaN3 |
| Recommended that the undiluted antibody be aliquoted into smaller working volumes (10-30 uL/vial depending on usage) upon arrival and stored long term at -20° C or -80° C, while keeping a working aliquot stored at 4° C for short term. Avoid freeze/thaw cycles. Stable for at least 1 year. |
| Target |
| 1103 |
| P28329. |
| Acetyl CoA choline O acetyltransferase antibody, Acetyl CoA:choline O acetyltransferase antibody, ChAT antibody, CHOACTase antibody, Choline acetylase antibody, choline acetyltransferase antibody, Choline O acetyltransferase antibody, Choline O-acetyltransferase antibody, CLAT_HUMAN antibody, CMS1A antibody, CMS1A2 antibody, EC 2.3.1.6 antibody, OTTHUMP00000019583 antibody, OTTHUMP00000019584 antibody |
| Choline acetyltransferase is a neuronal enzyme which catalyzes the reaction between Acetyl CoA and choline resulting in the formation of acetylcholine. It is therefore found primarily in cholinergic neurons making it a valuable marker for diseases associated with decreased cholinergic function such as Schizophrenia, Alzheimer's disease (AD) and Down syndrome (Holt et al. 1999). Decreased choline acetyltransferase activity in particular has been shown in Schizophrenic subjects (Karson et al 1993). It has furthermore been demonstrated that in patients with AD, there are significantly lower levels of cortical ChAT that correlate with severity of the disease as measured by loss of neuropsychological function (Baskin et al. 1999). |
| Application Dilution |
| WB |
1:300-5000 |
| IHC |
|
Powered by Bioz